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Resumen
En este artículo se describe un programa de 
terapia ocupacional adaptado para rehabilitar 
los efectos cognitivos secundarios asociados a 
la quimioterapia. Se incluye una revisión de 
la literatura de la rehabilitación cognitiva, así 
como de los ensayos farmacológicos utiliza-
dos para mejorar la cognición en pacientes 
de cáncer de mama. Se exponen dos estudios 
de caso ambulatorios de mujeres jóvenes pre-
menopáusicas afectadas de cáncer de mama 
(ambas portadoras de mutaciones del gen 
BRCA-1) para examinar la función de técnicas 
de terapia ocupacional adaptadas para el de-
sarrollo de estrategias compensatorias y para 
administrar rehabilitación cognitiva. La evalua-
ción neuropsicológica antes y después de la 
terapia ocupacional se utiliza para documentar 
el resultado de la terapia ocupacional adapta-
da para el rendimiento cognitivo. Los estudios 
de casos ilustran el perfil neuropsicológico de 
los cambios asociados a la quimioterapia y el 
curso de los déficits durante 7-9 meses. En 
los pacientes jóvenes, con estudios que de-
ben retornar a puestos de trabajo de ritmo 
rápido y competitivos, los efectos cognitivos 
secundarios postratamiento son especialmente 
nocivos, ya que los pacientes jóvenes adultos 
están construyendo sus vidas profesionales y 
no disponen del tiempo necesario de espera 
Abstract
This article describes a tailored occupatio-
nal therapy program to rehabilitate chemothe-
rapy-related cognitive side effects. A literature 
review of cognitive rehabilitation as well as 
pharmacological trials used to improve cogni-
tion in breast cancer patients is included. Two 
outpatient case studies of young women pre-
menopausally affected with breast cancer (both 
BRCA-1 gene mutation carriers) are used to 
discuss the role of tailored occupational the-
rapy techniques for developing compensatory 
strategies and for delivering cognitive remedia-
tion. Neuropsychological evaluation pre and 
post occupational therapy is used to document 
the result of tailored occupational therapy on 
cognitive performance. The case studies illustra-
te the neuropsychological profile of chemothe-
rapy-related cognitive changes and the course 
of deficits over 7-9 months. For younger, edu-
cated patients who must return to competiti-
ve, fast-paced jobs, cognitive side-effects post-
treatment are especially noxious as young adult 
patients are building their professional lives and 
are not necessarily provided time to wait for the 
usual trajectory of recovery to take its course.
Keywords: Breast cancer; adjuvant che-
motherapy; cognitive dysfunction; rehabili-
tation; occupational therapy; survivorship.
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para que la trayectoria habitual de recupera-
ción siga su curso.
Palabras clave: Cáncer de mama, qui-
mioterapia adyuvante, disfunción cognitiva, 
rehabilitación, terapia ocupacional, supervi-
vientes de cáncer.
the research to date on rehabilitation using 
cognitive, behavioral, and pharmacological 
interventions. We then provide clinical 
cases of young women impacted by 
cognitive side-effects and describe their 
course of tailored occupational therapy.
REHABILITATION STUDIES
While research has primarily been fo-
cused on elucidating the profile of cog-
nitive dysfunction post-chemotherapy, few 
studies have focused on treatment for these 
cognitive deficits. Behavioral interventions 
have included cognitive behavioral treat-
ment(15,16), an environmental intervention 
involving nature(17,18), cognitive rehabili-
tation training and computerized train-
ing(19,20), as well as cognitive remediation 
and compensatory strategies(21,22). 
Breast cancer survivors receiving 
cognitive behavioral treatment with 
Memory and Attention Adaptation Training 
(MAAT)(16) had significant improvement in 
verbal memory and spiritual well-being 
compared to controls. Improvements in 
other cognitive domains (i.e., executive 
functioning) or improvement in self-reported 
cognitive functioning or quality of life were 
not found. An environmental intervention 
designed to minimize attentional fatigue 
and restore attentional capacity in newly 
diagnosed stage I or II, breast-cancer 
patients status-post surgery patients 
included outdoor or leisurely activities 
that involved experiencing nature in some 
way (i.e., walking in a park, gardening, 
sitting by a pond, caring for pets) for three 
times a week for 20-30 minutes. Results 
INTRODUCTION
The field of cognitive rehabilitation for 
non-CNS cancers is in its nascent stage. 
Both cognitive remediation, a structured 
set of therapeutic activities designed to 
restore an individual’s ability to think, use 
judgment, and make decisions as well as 
compensatory strategies, tasks to augment 
an individual’s abilities, are used jointly in 
cognitive rehabilitation to improve quality 
of life and ameliorate the ability to function 
in work, at home, and in the community. 
Over the past decade, it has become 
evident that breast cancer and cancer 
treatment with adjuvant chemotherapy 
can result in cognitive dysfunction(1-7) 
and deficits can continue up to ten years 
post-chemotherapy(8). Deficits associated 
with chemotherapy are typically subtle 
and involve the domains of working 
memory, executive function, memory, and 
processing speed(1,3,4,9-13). A meta-analysis 
of mostly cross-sectional studies(14) found 
small to moderate effect sizes for difficulties 
in motor functions, executive functioning, 
learning and memory, spatial reasoning, 
and language functions.
For the majority of breast cancer 
survivors, cognitive side-effects ameliorate 
in 12-18 months(5). While the potential 
for recovery is ultimately good news, 
how does this recovery trajectory impact 
the increasing population of young adult 
breast cancer survivors? This subset of 
the population usually cannot wait 12-18 
months to recover their cognitive function 
in order to resume their occupational and 
domestic duties. In this article, we describe 
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maintained at 3 follow-up periods (6 
months, 14 months, and 26 months). In 
this small group of cancer survivors, length 
of time from active cancer treatment 
was unknown. In addition to memory 
improvement, the CBMEM group also 
had moderate effects for group-by-time 
interactions for decreases in depression 
and trait anxiety. Additionally, the CBMEM 
group had a small increase in performance-
based instrumental activities. They also had 
a significant increase in confidence about 
their everyday memory abilities, increased 
use of memory strategies, and less memory 
complaints. These gains were maintained 
at the fifteen month follow-up period.
Rehabilitative studies have typically 
had small samples(15-17,19-22) and not always 
required a cognitive complaint or a cogni-
tive deficit(17,18,21,22) .
PHARMACOLOGICAL STUDIES
There have been several clinical trials 
of stimulant medication as well as erythro-
poietin to improve cognitive side-effects as 
well as fatigue in cancer patients. To date, 
the studies of pharmacological agents have 
yielded inconclusive results. 
Modafinil
Modafinil has been studied to determine 
if it enhances cognitive functioning in 
patients with breast cancer(22). Sixty-eight 
participants with breast cancer who 
completed treatment with chemotherapy 
and/or radiation >1 month prior to 
commencement of the study completed 
both the open-label phase of the study 
(Phase 1) as well as the randomization 
phase to continued treatment with modafinil 
or placebo (Phase 2). Neither cognitive 
complaints nor measured cognitive deficits 
were among the study’s inclusion criteria. 
During Phase 1, all participants received 
100mg/d of modafinil for the first three 
indicated that individuals who engaged in 
the restorative intervention had improved 
attentional capacity over time(17). Patients 
who received high-dose chemotherapy and 
hematopoietic stem cell transplantation 
for systemic cancer were randomized to 
use either compensational strategies or an 
individualized, computer-based training 
software intervention to improve attention 
and memory or they were assigned to a 
control group. Training was implemented 
four times per week for one hour a day over 
the course of an inpatient stay. Significant 
improvements across all cognitive domains 
were found among the three study 
groups(19). Poppelreuter and colleagues 
(2009)(20) replicated this study with stage 
I and II breast cancer patients. They found 
similar results as with the hematopoietic 
stem cell transplantation study in that 
there were no specific intervention effects 
and concluded that cognitive remediation 
is unnecessary for breast cancer patients 
after adjuvant chemotherapy as cognitive 
deficits were only a transient problem. 
Cognitive remedial and compensatory 
training using the Cognitive-Behavioral 
Model of Everyday Memory (CBMEM) 
which targeted health promotion 
instruction, memory strategies, and skill 
building in eight, 75-minutes sessions 
conducted over four weeks was studied 
in a retirement community of individuals 
with chronic illness, eleven of which were 
identified as cancer survivors(21). Cancer 
survivors showed significant improvements 
in short-term memory as well as subjective 
aspects of memory self-efficacy and meta-
memory from pre-test to post-test. In a 
follow-up study, McDougall (2011)(22) 
found that cancer survivors (including 
breast, prostate, uterine, lymphoma and 
leukemia, throat, facial and/or basal cells 
on the nose) randomized to either CBMEM 
or a health training group that emphasized 
successful aging had improved memory 
after either intervention and improvement 
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days followed by 200mg/d of modafinil for 
four weeks. After four weeks, Phase 2 was 
initiated and participants were randomized 
to an additional four weeks of treatment 
with modafinil or placebo. Results indicated 
that 200mg/d of modafinil during Phase 
1 significantly increased participants’ 
ability to store, retain, and retrieve verbal 
and non-verbal information. These results 
were also found at the end of Phase 2 for 
individuals receiving continued treatment 
with modafinil. Further, increased 
sustained attention was also found at the 
end of Phase 2 for individuals receiving 
modafinil. Modafinil had no effect on 
working memory or brief attention in 
either phase. 
In an advanced cancer patient 
population, modafinil’s effect on cancer-
related cognitive dysfunction has also 
been studied(24). Twenty-eight patients with 
advanced cancer (breast, genitourinary, 
gastrointestinal, head/neck, hematologic, 
lung, other) participated in a double-
blind, randomized, cross-over, single-dose 
trial of modafinil where patients were 
randomly assigned to receive a single dose 
of 200mg modafinil or placebo on day one 
and were crossed over to the alternative 
treatment on day four. Complaint or 
demonstration of cognitive dysfunction 
was not an inclusion criterion. Attention 
and psychomotor speed were assessed 
before tablet intake on each day and again 
four and a half hours after tablet intake 
on each day. Significant improvements 
were found in both finger tapping with 
the dominant hand and on a psychomotor 
speed, shifting task after treatment with 
modafinil compared with placebo. Taken 
together, these studies provide preliminary 
data regarding the potential efficacy of 
modafinil in improving cancer-related 
cognitive dysfunction. 
Improved attention, psychomotor 
speed, and retention of information have 
been found with modafinil. However nei-
ther study required cognitive complaints 
nor measured cognitive deficits as inclu-
sion criteria(23,24). 
Dexymethylphenidate (d-MPH)
Dexymethylphenidate (d-MPH) was 
studied to determine whether or it could 
ameliorate cognitive dysfunction and 
fatigue in women undergoing adjuvant 
chemotherapy(25). During chemotherapy 
for breast cancer women were randomized 
to d-MPH (N=29) or placebo (N=28) to 
see if it improved cognitive functioning, 
QOL, or fatigue. Participants were eligible 
for the study if they planned to receive 
at least four cycles of a standard regimen 
of chemotherapy for fully resected breast 
cancer. Complaints of fatigue or cognitive 
problems were not required inclusion 
criteria. Women were recruited after 
one cycle of chemotherapy. They started 
on 5 mg bid of placebo for one cycle 
of chemotherapy. If they demonstrated 
compliance with the placebo, they were 
randomized to d-MPH 5 mg bid or to 
matched placebo. If this regimen was 
well tolerated, the dose was increased 
to 10 mg bid one week later. If 10 mg 
bid was not well-tolerated, a decrease to 
5 mg bid was made. Patients took either 
5 mg bid or 10 mg bid (whichever they 
tolerated) until the end of their final cycle 
of chemotherapy. There were no significant 
differences in cognitive functioning, QOL, 
or fatigue at any of the assessments. In the 
d-MPH group, patients classified as having 
moderate to severe cognitive dysfunction 
decreased from 3.6% at baseline to 0% 
at the end of chemotherapy. Rate of 
impairment was stable at 11% in the 
placebo group. However, a correction 
factor applied for practice effects at the 
follow-up assessments led to 11% with 
moderate to severe impairment in the 
d-MPH group and 22% in the placebo 
group. Twelve of the patients had grade 
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3 toxicity during treatment. Four patients 
had an adverse event suspected to be 
related to study medication. Eight patients 
in each arm required dose adjustment of 
their study drug due to presumed toxicity. 
A total of 18 patients discontinued the 
study medication before the end of the 
study (12 in the d-MPH group and 6 in 
the placebo group). Some withdrew study 
consent, some participants stopped their 
chemotherapy, some had neurotoxicity 
presumed secondary to the study drug, 
two had presumed study drug toxicities, 
and two withdrew for other reasons. Only 
20% of patients in either group were 
interested in continuing the study drug 
were they given this option. The major 
study limitation was that women were 
reluctant to take medication and thus, the 
accrual goal was not met and the study 
was underpowered. 
In another study, Lower et al. (2005) (26) 
conducted a randomized placebo control 
trial of d- MPH as a treatment for cogni-
tive dysfunction and fatigue in non-anemic 
breast and ovarian cancer patients. Patients 
were eligible if they were treated with > to 
4 cycles of chemotherapy and had com-
pleted chemotherapy at least 2 months pri-
or to study entry. Patients who completed a 
single-blind placebo period without symp-
tomatic improvement were randomized to 
an 8 week double blind phase. Placebo 
or d-MPH was adjusted from 10-50 mg 
per day and maintained for > 2 weeks. 
One hundred fifty two patients (76% 
breast cancer and 13.6% ovarian cancer) 
were randomized to placebo (N=75) or d-
MPH (N=77). Significant improvement in 
memory and fatigue was observed in the 
d-MPH group. The mean highest dose of 
d-MPH was 27.5 mg/day. The d-MPH was 
well tolerated in breast and ovarian cancer 
patients. 
Thus, the results from these two studies 
reveal that the efficacy of d-MPH in treating 
cancer-related cognitive side-effects is 
inconclusive but better results were found 
when using d-MPH post-chemotherapy(26).
Erythropoietin
While studies of epoetin-alpha 
with breast cancer patients undergoing 
chemotherapy have been mixed(27,28), since 
these studies were published Bohlius et 
al. (2009)(29) completed a meta-analysis of 
nearly 14,000 patients (including breast 
cancer patients) from 53 trials conducted 
worldwide and found increased on-study 
mortality and worsened overall survival in 
cancer patients receiving erythropoiesis-
stimulating agents (including epoetin-
alpha). 
CLINICAL CASES
As the review of published treatments 
shows there is a lack of evidence based 
treatments for chemotherapy-related 
cognitive deficits. Thus, we present two 
cases of premenopausal young women 
each with a positive BRCA-1 gene mutation 
who complained of cognitive side-effects 
following chemotherapy. Their medical 
course, neuropsychological functioning 
(pre and post cognitive rehabilitation), 
and an Occupational Therapy intervention 
tailored to treat their deficits is reviewed. 
One patient was also unsuccessfully 
treated with methylphenidate following 
her Occupational Therapy treatment.
Patient 1
Patient 1 was a 24-year-old woman, 
with no significant medical history when 
she presented to her gynecologist because 
of a suspicious mass she discovered on 
self-examination in her right breast. Breast 
ultrasound revealed a suspicious mass at 
the 9 o’clock area measuring 3.0 X 1.7 X 
2.9cm. Patient 1 underwent a right breast 
core biopsy, which revealed a poorly dif-
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treatment, she complained of cognitive 
delays and memory problems. Two months 
after finishing chemotherapy she began 
Tamoxifen. She declined radiation therapy. 
Patient 1 denied ever having a head in-
jury, loss of consciousness, seizure or any 
neurological disorder. Family neurologic 
history includes temporal lobe epilepsy, 
in her mother. She denied any history of 
toxic chemical exposure. She also denied 
that her mother experienced any perinatal 
problems or difficulties with labor and de-
livery of Patient 1. Patient 1 denied tobacco 
use and drinks alcohol socially, one drink 
a week. She denied using illicit drugs.
Her neuropsychological evaluation 
took place one month from finishing adju-
vant chemotherapy as she had returned to 
work and was having difficulty performing 
her job. 
Chief Complaint: “I can’t focus. My 
mind drifts. I can accomplish simple tasks 
at work. I can’t sleep.” She also com-
plained of word-finding difficulties and 
said she uses a lot of “filler” words. Patient 
1 reported trying to write a personal state-
ment for graduate school applications but 
could only write 3-4 sentences and then 
her mind would drift. 
Psychiatric History: Patient 1 was seen 
for psychiatric consultation as requested 
by her oncologist. The consultation was 
precipitated by Patient 1’s mother calling 
the oncologist and reporting that Patient 
1 cried for hours each day, declined to 
leave her room, and stayed up all night 
searching the internet for information on 
the BRCA mutation. Patient 1 was seen 
by psychiatry during her adjuvant chemo-
therapy treatment. Patient 1 had no past 
psychiatric history, and her family psychi-
atric history was negative. Her psychiatric 
diagnosis was Adjustment Disorder with 
Mixed Anxiety and Depressed Mood, rule 
out of Mild Major Depressive Episode. The 
psychiatrist noted that Patient 1 presented 
as very well defended and appeared to 
ferentiated invasive ductal carcinoma with 
focal micropapillary features that was es-
trogen receptor (ER) and progesterone re-
ceptor (PR) positive and negative for the 
human epidermal growth factor receptor-2. 
A FDG PET scan was conducted and nega-
tive for any distant metastases. A bilateral 
mammogram revealed a 3cm nodularity in 
the posterior portion of the right breast and 
a bilateral breast MRI performed on the 
same day revealed a 1.8 X 2.2 X 2.7cm 
enhancing mass in the posterolateral right 
breast. The left breast was unremarkable. A 
fine needle aspiration of the right axillary 
lymph node was negative. Patient 1’s stage 
was T2N0M0 (Stage IIA). 
After genetic testing revealed that 
Patient 1 was positive for the BRCA-1 gene 
mutation, she decided to undergo bilateral 
mastectomy with immediate expander 
reconstruction. Right mastectomy revealed 
T2N0MO invasive ductal carcinoma, 
moderately to poorly differentiated, 
measuring 2.4cm with lymphovascular 
invasion present with ER and PR levels 
of 98 and 95 respectively. Right sentinel 
lymph node biopsy revealed five negative 
lymph nodes on H&E and cytokeratin. The 
left mastectomy specimen was unrevealing. 
Patient 1’s postoperative clinical course 
was unremarkable as she continued 
to undergo expansion. Oncotype DX 
testing revealed a score of 29, suggesting 
a 20% chance of distant recurrence. 
CA125 was 200 and systemic therapy 
was recommended. Prior to starting 
chemotherapy she underwent ovarian 
egg retrieval where 24 oocytes were 
retrieved after which she was diagnosed 
with ovarian hyper-stimulation syndrome 
and put on Oxycodone. Following the 
resolution of her ovarian hyper-stimulation 
syndrome she started and completed an 
adjuvant chemotherapy regimen which 
consisted of 4 cycles of doxorubicin and 
cyclophosphamide followed by 4 cycles 
of paclitaxel. After her ACT chemotherapy 
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be making a visible effort to “hold it to-
gether.” Patient 1 was offered the option 
of starting antidepressant therapy, but she 
declined. She preferred to have psycho-
therapy with her social worker with whom 
she was familiar. Patient 1 was prescribed 
lorazepam prn by her oncologist. Patient 
1 met with her social worker a couple of 
times during her chemotherapy treatment. 
Patient 1 stated that she was fine 90% of 
the time and when she was not fine, it 
was not her scheduled appointment time 
so, she stopped therapy. At the time of 
the neuropsychological evaluation, she 
described her mood as “not bad. I’m a 
pretty happy person overall. There’s a dif-
ficult situation in my life now but what can 
you do?” Patient 1 stated she was angry 
that she had agreed to chemotherapy and 
said she would “rather die in 10 years than 
be stupider for having had chemotherapy.” 
Despite this statement, Patient 1 denied 
suicidal ideation.
Patient 1 complained of insomnia with 
delayed sleep phase and interrupted sleep. 
She reported trying diphenhydramine HCl 
to help her sleep. She stopped taking it three 
days prior to her initial neuropsychological 
evaluation. She reported her insomnia has 
worsened since she finished chemotherapy. 
She denied feeling anxious and reported 
taking lorazepam only three times. Once 
she took it at her doctor’s urging, and twice 
to sleep. However, it did not help her sleep. 
Psychosocial/Occupational/Academic 
Functioning: Patient 1 was single and lived 
alone. She worked as a trade analyst for 
the French government and was primarily 
responsible for trade promotion. Her job 
duties required a great deal of translating, 
writing the monthly newsletter, and main-
taining the website. She reported that her 
employer was very supportive of her and 
very flexible in letting her take time to go 
to medical appointments. Prior to her diag-
nosis, Patient 1 intended to start a graduate 
school program at a top tier school. Instead 
she deferred admission and began her can-
cer treatment. 
Patient 1 had always been in excellent 
student. She received in a full scholarship 
to a competitive college. She was in the 
Honors program at college and graduated 
with an “A” average. In college, she majored 
in social science and French. She reported 
that her admission test for business school 
was in the 99th percentile. She is fluent in 
French and is conversant in Spanish and 
German. She denied ever being diagnosed 
with a learning disability or attention 
deficit disorder. Patient 1 reported having 
a good support system with her family and 
Table 1. Neuropsychological Assessment Tests Used
Neuropsychological tests administered: Advanced Practice Solutions subtest: 
Reliable Digit Span(38); Beck Depression Inventory – Fast Screen (BDI-Fast Screen)(39); 
Boston Naming Test(40); California Verbal Learning Test-Second Edition (CVLT-II)(41); 
Continuous Performance Test-II (CPT-II)(42); Controlled Oral Word Association Test(43,40); 
Delis Kaplan Executive Function System (DKEFS) Selected Subtests: Color Word 
Interference Test, Category Fluency(44); North American Adult Reading (NAART)(45); 
Paced Auditory Serial Addition Test (PASAT)(46); Personality Assessment Inventory(30,34); 
Rey Complex Figure Test(35); Test of Memory Malingering (TOMM)(47); Trail Making 
Test, Part A and B(40); Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) 
Selected Subtests: Arithmetic; Digit Span, Coding, Symbol Search(48); Wechsler 
Memory Scale-Fourth Edition (WMS-IV) Selected Subtests: Logical Memory I&II, 
Recognition(49); Wide Range Achievement Test IV - Reading subtest(50); Wisconsin 
Card Sorting Test(37).
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Table 2. Patient 1: First Neuropsychological Evaluation
(1 month post-chemotherapy)
Test Score Percentile Interpretation Norms/Reference
Motivation
CPT-II Valid Conners, 2004(42)
Reliable Digit Span Raw=8 >25 Above cut-off Pearson, 2009(38)
CVLT-II Forced Choice Raw=16/16 Valid Delis et al. 2000(41)
PAI T-Score Morey, 2009(34)
Inconsistency 52
Infrequency 55
Negative Impression Management 47
Positive Impression Management 52
Premorbid IQ Estimate
North American Adult Reading Test Standard Score Percentile Blair & Spreen, 1989(45)
Estimated FSIQ 118 88 High Average
Attention
WAIS-IV Standard Score Percentile Wechsler, 2008(48)
Working Memory Index 108 70 High Average
Working Memory Subtests Scaled Score Percentile
Arithmetic  9 63 Average
Digit Span 14 91 Superior
  Digit Span Forward 10 50 Average
  Digit Span Backward 16 98 Very Superior
  Digit Span Sequencing 14 91 Superior
Reliable Digit Span >25 Above cut-off
Continuous Performance Test-II T-Score* Percentile Conners, 2004(42)
Omissions 57 76 Within Normal
Commissions 71 98 Markedly Atypical
Hit RT 40 18 A little fast
Hit RT SE 68 97 Markedly Atypical
Variability 76 99 Markedly Atypical
Detectability 62 89 Mildly Atypical
Response Style 46 35 Within Normal
Perseverations 47 41 Within Normal
Hit RT Block Change 49 49 Within Normal
Hit SE Block Change 69 97 Markedly Atypical
Hit RT ISI Change 60 85 Mildly Atypical
Hit SE ISI Change 84 99 Markedly Atypical
*Scores are reversed scored
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Test Score Percentile Interpretation Norms/Reference
Paced Auditory Serial Addition Test z-score Percentile Rao et al. 1991(46)
(PASAT)
3 seconds 0.06 52 Average
2 seconds 0.94 83 High Average
Information Processing Speed
WAIS-IV Standard Score Percentile Wechsler, 2008(48)
Processing Speed Index 114 82 High Average
Processing Speed Subtests Scaled Score Percentile 
Coding 13 84 High Average
Symbol Search 12 75 High Average
Trail Making T-Score Percentile Heaton et al. 2004(40)
Trails A 71 98 Very Superior
Language Functioning
Verbal Fluency Scaled Score Percentile
Letter Fluency T=52 58 Average Heaton et al. 2004(40)
Category Fluency 13 84 High Average Delis et al. 2001(44)
T score
Boston Naming Test 56 73 Average Heaton et al. 2004(40)
Visual Spatial
Rey Complex Figure Test Raw Score Percentile Meyers & Meyers, 
1995(35)
Copy 35 >16 Average
Executive Functioning
Trail Making T-Score Percentile Heaton et al. 2004(40)
Trails B 51 54 Average
Color Word Interference Scaled Score Percentile Delis et al. 2001(44)
Color Naming  9 37 Average
Word Reading  11 63 Average
Inhibition  9 37 Average
Inhibition/Switching  1 <1 Impaired
Memory
WMS-IV Scaled Score Percentile Wechsler, 2009(49)
Logical Memory I 11 63 Average
Logical Memory II 11 63 Average
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Test Score Percentile Interpretation Norms/Reference
Recognition Raw=25 26-50% Average 
Rey Complex Figure Test T-Score Percentile Meyers & Meyers, 
1995(35)
Immediate Recall 16.5 2 Impaired
Delayed Recall 15.5 1 Impaired
Recognition 23 82 High Average
CVLT-II z-Score Percentile Delis et al. 2000(41)
Learning Slope  1 84 High Average
Trials 1-5 Total T=49 46 Average
SDFR  0 50 Average
SDCR  0.5 69 Average
LDFR  0 50 Average
LDCR  0.5 69 Average
Recognition -0.5 31 Average
False Positives -0.5
 
31 Average
Behavioral and Emotional 
Functioning
PAI Score Morey, 2009(34)
Inconsistency 52
Infrequency 55
Negative Impression Management 47
Positive Impression Management 52
Somatic Complaints 58
Anxiety
Anxiety-Related Disorders
Depression
Mania
Paranoia
Schizophrenia
Borderline Features
Antisocial Features
Alcohol Problems
Drug Problems
Aggression
Suicidal Ideation
Stress
Nonsupport
Treatment Rejection
Dominance
Warmth
48
51
60
56
45
53
51
53
49
54
40
49
50
39
53
54
54
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she could turn to for support. Consistent 
with her reluctance to engage in psychi-
atric treatment or supportive counseling, 
her profile revealed that her motivation for 
treatment is substantially lower than most 
adults. Her responses suggested that she 
was satisfied with herself as she was and 
that she was not exhibiting significant psy-
chopathology. Thus, she saw little need for 
changes in her behavior.
The cognitive assessment revealed 
adequate motivation to perform her best. 
Significant attentional difficulties were 
revealed. On a continuous performance 
task, Patient 1 had problems quickly and 
efficiently processing stimuli. Her responses 
were more erratic when inter-stimulus 
intervals slowed. Also, her responses were 
less consistent as the test progressed. Patient 
1 exhibited variability in her learning and 
working memory, which is consistent with 
attentional lapses. Testing of the limits on 
mental arithmetic by allowing her to use 
pencil and paper, improved her score. Her 
recognition for a word list was lower than 
expected for her premorbid IQ estimate as 
were her making two false positive errors 
on recognition. Her immediate and delayed 
visual memory was deficient largely due 
to the haphazard and unorganized manner 
in encoding a previously seen figure. On 
executive functioning, she had impaired set 
shifting when shifting between inhibiting 
and not inhibiting a response. Her 
performance on reciprocal inhibition was 
lower than expected (given her premorbid 
IQ estimate). She also had a very mild 
dysnomia. Notably, her processing speed 
was an area of strength. Verbal memory 
(word list retrieval and narrative retrieval) 
was within normal limits. 
The results of the evaluation were 
consistent with Patient 1’s complaints of 
inattention, distractibility and to a lesser 
extent, word finding problems. Her 
daily life was impacted by her cognitive 
difficulties. She reported being unable to 
friends from college that she sees every 4-5 
days. She texts and speaks often with her 
boyfriend. 
Behavioral Observations: Patient 1 
was unaccompanied to the appointment. 
She was oriented in all spheres. Patient 
1’s gait appeared normal. No extraneous 
movements were observed. Her speech 
was fluent and of normal rate and volume. 
Patient 1 was personable, friendly, and 
made good eye-contact. Her attitude toward 
testing was positive, and she exerted good 
effort. Mood was euthymic. Patient 1 was 
slightly tangential in her thought process. 
There was no evidence of hallucinations, 
delusions, or compulsions. Patient 1 was 
anxious about her cognitive difficulties and 
angry that she had agreed to chemotherapy 
as she said she “knew it would make her 
stupid.” Following the assessment, Patient 
1 became tearful when discussing her 
current cognitive difficulties.
Neuropsychological Assessment: (see 
Table 1 for the various neuropsychological 
tests used in the case studies presented). 
Table 2 presents the individual 
neuropsychological tests used with Patient 
1. Tests that were 1.5 standard deviations 
below the premorbid IQ estimate were 
considered lower than expected.
At the time of the evaluation, Patient 1 
described herself as a pretty happy person 
overall (but had been seen by a psychia-
trist during adjuvant chemotherapy and 
was prescribed lorazepam, which she took 
3 times). Her responses on the Personality 
Assessment Inventory (30) revealed mild or 
transient depressive symptomatology. She 
denied suicidal ideation. Patient 1 was 
very independent and had a tendency to 
present herself in a positive light such that 
she would deny problems. For instance, 
she reported having a stress level compa-
rable to that of normal adults which was 
inconsistent with her life situation at the 
time of the evaluation. However, she also 
reported having a large social network that 
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complete graduate school applications and 
had decreased job performance. Without a 
premorbid neuropsychological assessment 
(conducted prior to her cancer or its 
treatment), it is impossible to determine the 
exact causation of Patient 1‘s attentional 
difficulties. However, her negative 
premorbid history for cognitive problems, 
her neuropsychological profile, and her 
subjective complaints are consistent with 
chemotherapy-related cognitive side-
effects. Patient 1 was assessed only 1 month 
post-chemotherapy and thus, it was likely 
her cognitive side-effects would gradually 
resolve. However, she was impatient to 
have her cognition return to her usual high 
functioning state as she planned to attend 
a graduate school program in 8-9 months. 
Since her insomnia could be contributing to 
her cognitive she was prescribed zolpidem 
to help restore her circadian rhythm. After 
a two week course of zolpidem Patient 1’s 
sleep was restored, and she was referred 
for cognitive rehabilitation.
Occupational Therapy
Patient 1 presented to Occupational 
Therapy for evaluation and treatment of 
impaired cognition/attention. She was 
managing all basic and instrumental 
activities of daily living without reporting 
any difficulty and no safety concerns were 
identified during the initial evaluation or 
course of treatment. She completed the 
Montreal Cognitive Assessment (MOCA)(31) 
with a score of 30/30. This patient reported 
her most significant impairments are noted 
during work tasks. She reported difficulty 
initiating and attending to Power Point slide 
presentations she created, often finding 
she stared blankly at the computer screen. 
She also reported difficulty with reading 
100 pages of a document and recalling all 
information read, as well as synthesizing it 
into another format, such as conversation 
or written communication.
At the time of evaluation, it was 
determined that Patient 1 would attend 
one Occupational Therapy treatment 
session each week for the following 4 
weeks. The frequency of once per week 
was determined in order to allow the 
patient time to implement the personalized 
strategies learned in session. This 
schedule facilitates time to practice these 
interventions and provide personalized 
feedback to the clinician regarding 
effectiveness and frequency of strategy 
use. The patient and clinician together 
can then modify the strategies or choose 
new ones to implement. The duration of 4 
weeks was determined to allow sufficient 
time to implement learned strategies and 
allow these to develop into habits. At the 
completion of 4 weeks’ time, the plan was 
for re-evaluation to assess for any changes 
in functional status. Areas of deficit to be 
addressed included time management, 
organizational strategies for daily planning 
of work tasks, shifting between tasks 
at work, and reading comprehension 
with superior encoding and retrieval of 
information. 
Of note, upon completion of the 
evaluation, the clinician provided several 
simple strategies for easy and quick 
implementation at work in order to improve 
daily task management and flow. Strategies 
included use of a computerized calendar 
(such as Outlook or other comparable 
software) to provide time reminders to 
transition between tasks, as well creating 
a daily schedule in the morning to provide 
structure and organization to daily tasks 
and responsibilities. The patient stated 
that she would try implementing these 
strategies, however verbalized a desire for 
more sophisticated ways of improving her 
cognitive skills. 
Patient 1 completed 3 treatment sessions 
in addition to the initial evaluation, with 
approximately 2 weeks between sessions, 
due to patient’s schedule. The first session 
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focused on strategies to implement in 
order to maintain attention to task during 
free writing or Power-Point presentation 
composition at work. The patient was 
provided with a 5 step process(32) to check 
whether she was staying on task, as well 
as strategies such as imagery/visualization, 
using external cues and completing self-
checks throughout a task. The 5 step 
process to focus her attention included the 
following: Stop (think, “what am I doing? 
What is my objective?”), Define (the main 
task), List (the steps), Learn (the steps and 
repeat them so they become automatic/
easily retrieved), and Check (“Am I doing 
what I planned to do?”). The patient 
verbalized understanding of these strategies 
and said she would try implementing them 
during the week. 
The second and third treatment sessions 
focused on reading comprehension and 
synthesizing information read into a 
written summary. The patient read a self-
selected article from New York Times, using 
a highlighter and was given verbal cues to 
stop every 3-4 paragraphs to summarize 
aloud what she had read. The patient was 
able to verbally summarize the article 
content every few paragraphs however, 
she demonstrated difficulty with a written 
summary of the salient article points upon 
completing the article. When asked 2 
detailed questions taken from content in 
the article, the patient needed to reference 
the article to provide the proper answer.
Throughout the New York Times article 
activity, the patient stated that reading 
items of this nature was not as challenging 
as required readings for her anticipated 
graduate studies. Despite her statement, 
the patient was observed to have mild 
difficulty with this activity. Additionally, 
the patient reported that she was having 
more difficulty with this type of activity 
when the reading material was in French. 
In order to address this perceived deficit, 
the clinician structured a similar activity 
in French in order to better simulate the 
patient’s work tasks.
During this patient’s third session, 
the Occupational Therapist(33) (as well as 
another clinician who is fluent in French) 
was present. The patient again selected an 
article to read, this time from Le Parisien, 
a French newspaper. The patient read this 
article, using a highlighter as needed, 
with verbal cues to stop and summarize 
content every few paragraphs. All follow-
up questions were written by GM, shown 
to the French speaking therapist, and 
then read aloud in French. The patient 
was able to respond to the questions and 
explain answers in French, with minimally 
increased time. This clinician then asked 
the patient to write a synopsis of the article 
in French. The patient was able to do this, 
writing one paragraph in approximately 
10 minutes. The patient reported that 
this activity was moderately challenging. 
Plans were made to review patient-written 
synopsis and continue to address areas of 
deficit at the next treatment session.
After completion of this third session, 
GM reviewed the patient-written synopsis 
with the French-speaking clinician. 
Several grammatical and gender errors 
were noted with this written synopsis in 
the patient’s second language, French. 
This feedback was not given to the patient 
though, because she did not return for next 
scheduled appointment. Patient 1 did not 
respond to further attempts to schedule 
Occupational Therapy and complete her 
course of treatment.
Reflection
Patient 1 initially stated that she func-
tions at a very high cognitive level, and will 
be attending an intense academic graduate 
program. While the Occupational Thera-
pist(33) explained that Occupational Ther-
apy approaches include both remediation 
and compensatory strategies, this patient 
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Table 3. Patient 1: Comparison of Neuropsychological Scores on Selective Tests 
Found to be Impaired or Lower than Expected
Premorbid IQ Estimate
Standard Score Percentile Interpretation
North American Adult Reading 
Test 118 88 High Average
Baseline 
(1 Month Post-Chemotherapy)
Re-Evaluation after OT
(7.5 Months Post-Chemotherapy)
Test Score % Interpretation Score % Interpretation
Attention
WAIS-IV Scaled %  Scaled %
Arithmetic 9 37 Average 12 (13)* 75 (84) High Average
Continuous Performance Test-II T-Score* % T-Score* %
Omissions 57 76 Within Normal 47 39 Within Normal
Commissions 71 98 Markedly Atypical 66 96 Markedly Atypical
Hit RT 40 18 A little fast 47 40 Within Normal
Hit RT SE 68 97 Markedly Atypical 38 12 Good performance
Variability 76 99 Markedly Atypical 43 26 Good performance
Detectability 62 89 Mildly Atypical 67 96 Markedly Atypical
Response Style 46 35 Within Normal 48 45 Within Normal
Perseverations 47 41 Within Normal 47 41 Within Normal
Hit RT Block Change 49 49 Within Normal 67 96 Markedly Atypical
Hit SE Block Change 69 97 Markedly Atypical 63 91 Mildly Atypical
Hit RT ISI Change 60 85 Mildly Atypical 40 17 Good performance
Hit SE ISI Change 84 99 Markedly Atypical 47 36 Within Normal
*Scores are reversed scored
Executive Functioning
Color Word Interference Scaled % Scaled %
Color Naming  9 37 Average  8 25 Low Average
Word Reading 11 63 Average 14 91 Superior
Inhibition  9 37 Average 11 63 Average
Inhibition/Switching  1 <1 Impaired 13 84 High Average
Language
Boston Naming Test T Score % T Score %
56 54 Average 67 92 Superior
Memory
Wechsler Memory Scale-IV Scaled % Scaled %
Logical Memory I 11 63 Average 15 95 Superior
Logical Memory II 11 63 Average 14 91 Superior
Recognition Raw=25/30 26-50% Average Raw=28/30 >75% Within Normal
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California Verbal Learning Test-II 
(CVLT-II)
z Score % z Score %
Learning Slope 1 84 High Average -0.5 31 Average
Trials 1-5 Total 49=T 46 Average 54=T 66 Average
SDFR 0 50 Average 0 50 Average
SDCR 0.5 69 Average 0.5 69 Average
LDFR 0 50 Average 0 50 Average
LDCR 0.5 69 Average 0 50 Average
Recognition -0.5 31 Average 0 50 Average
False Positives -0.5 31 Average 0.5 69 Average
Rey Complex Figure Test T Score % T Score %
Copy 35 >16 Within Normal 32 2-5 Mildly Impaired
Immediate Recall 29 2 Impaired 48 42 Average
Delayed Recall 27 1 Impaired 44 27 Average
Recognition 59 82 High Average 60 84 High Average
barrier to both a successful Occupational 
Therapy outcome and improved cognitive 
functional performance in her daily life. 
The patient terminated Occupational 
Therapy by avoiding further contact with 
her Occupational Therapist, thus there was 
no closure to her course of Occupational 
Therapy treatment. Her behavior was also 
borne out in her Personality Assessment 
Inventory(33), where she indicated a 
reluctance to engage in psychiatric 
treatment or supportive counseling. Her 
profile revealed that her motivation for 
treatment is substantially lower than 
most adults. Thus, there is a defensive 
personality style that makes it difficult for 
her to confront deficits and actively engage 
in working on difficulties. 
Following her course of Occupational 
Therapy treatment, two weeks later she 
was started on methylphenidate 5 mg. She 
reported taking methylphenidate only a 
few times but it made her hyperactive so, 
she discontinued it. She was prescribed 
modafinil but her insurance company re-
fused to authorize its use for cognitive 
problems. 
Neuropsychological Re-Evaluation: Ta-
ble 3 presents the individual neuropsycho-
demonstrated resistance to implementing 
compensatory strategies. Patient 1 wanted 
her cognitive function to restored to her 
premorbid level, without implementing 
new strategies to facilitate her previous 
high level of functioning. It appeared that 
Patient 1 did not complete Occupational 
Therapy due to the challenging nature of 
the last activity. Patient 1 may not have 
wanted to confront the fact that there were 
errors in her simple written paragraph, and 
thus did not return to therapy. 
The largest barrier to treatment success 
with Patient 1 was her lack of engagement 
in the therapy process. From the initiation of 
Occupational Therapy, Patient 1 verbalized 
that she wanted her cognitive function to 
be restored to its prior level, without having 
to change how she performs her work tasks 
or implement compensatory strategies. 
Throughout the course of Occupational 
Therapy treatment, it was reinforced 
to Patient 1 that in order to achieve a 
successful outcome with both work tasks 
and future enrollment in an academically 
intense graduate program, she may have 
to implement compensatory or “study” 
strategies. This patient was resistant to this 
concept throughout treatment, creating a 
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logical tests used in Patient 1’s re-evaluation. 
Tasks that Patient 1 exhibited difficulty with 
were repeated (see Table 1 for all neuropsy-
chological tests). Tests that were 1.5 stand-
ard deviations below the premorbid IQ esti-
mate were considered lower than expected.
Patient 1 was re-evaluated three 
months after her course of Occupational 
Therapy treatment and 7.5 months post-
chemotherapy. At the time of her re-
evaluation, she was taking tamoxifen 20 
mg. She reported problems with attention 
/ concentration, problem solving, and 
memory. Her complaints were not as 
severe as at her initial evaluation and she 
indicated she was less “foggy” and tasks 
were less frustrating for her.
Results of the re-evaluation indicated 
a significant improvement in Patient 
1’s memory, cognitive flexibility, and 
word finding. Her visual memory both 
immediately and at delayed recall, 
improved from the impaired to the average 
range. Her memory for narratives improved 
from average to superior. Recognition for a 
word list and overall list learning (Trials 
1-5) improved as well. She also exhibited 
improved confrontation naming (average 
to superior). Thus, there is no longer any 
evidence of a mild dysnomia. Lower 
than expected performance on reciprocal 
inhibition improved and shifting between 
inhibiting and not inhibiting a response 
improved from impaired to high average. 
Mental arithmetic also improved. Results 
on a sustained attention task suggested 
improvement in her reaction time as well 
as less variability and better consistency 
in her reaction time over the course of 
the task. Despite these improvements, 
inattention and poor vigilance were still 
apparent. Inattention to details on her copy 
of the Rey Complex Figure(35) was also seen 
however, as stated above, her recall (of the 
figure) improved. 
Patient 1 appeared to be demonstrating 
the typical trajectory of improvement in 
cognitive functioning post-chemotherapy. 
Attention and vigilance appeared to con-
tinue to be deficits. Despite taking tamox-
ifen, she did not report noticing any decre-
ment in her cognitive functioning, and her 
neuropsychological re-evaluation shows 
overall improvement. She was encouraged 
to use academic support services when she 
began her graduate studies.
Patient 2 
Patient 2 was a 36-year-old woman who 
presented to her gynecologist with a noted 
mass in her right breast with a past medical 
history that was significant for a sinus infec-
tion and a heart murmur. She also had a 
history of uterine fibroids and ovarian cysts. 
Six years prior she discovered a different 
mass in her left breast that was biopsied and 
found to be benign. PET imaging showed 
two adjacent nodules in the upper central 
right breast spanning 2.7 cm. One nodule 
was 1.2cm, the other 0.7cm. Subsequent 
core biopsies showed a poorly differenti-
ated invasive ductal carcinoma that was 
estrogen receptor (ER) and progesterone re-
ceptor (PR) negative and negative for the 
human epidermal growth factor receptor-2. 
Patient 2’s stage was T2N0MO (Stage IIA). 
A breast MRI was performed pre-
operatively to determine her anatomy and 
revealed a 2.2cm lesion at the 10 o’clock 
position in her right breast consistent with 
two lesions close together. One lesion 
measured 8m and the other appeared to be 
1.5cm away. Patient 2 then underwent MRI 
needle localization followed by a partial 
mastectomy and sentinel lymph node 
biopsy. Pathology showed three sentinel 
lymph nodes that were all free of cancer 
and a 2.5mm grade III, poorly differentiated 
invasive ductal carcinoma. The medial 
margin did show a second focus of cancer 
measuring 9mm. Genetic testing revealed 
that Patient 2 was positive for the BRCA-
1 gene mutation, but she decided against 
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pursuing a prophylactic mastectomy. Prior 
to starting chemotherapy, she underwent 
ovarian egg retrieval where 6 oocytes were 
retrieved for fertility preservation. 
She completed four cycles of taxotere 
and cyclophosphamide (TC) chemotherapy 
which was followed by radiation therapy. 
She experienced a chemotherapy 
extravasation which resulted in left thumb/
wrist and forearm pain. She was seen by 
Occupational Therapy and was treated with 
a splint to immobile her wrist and thumb. 
Following the completion of her adjuvant 
chemotherapy, she experienced hot flashes 
and mild sensorimotor polyneuropathy 
which presented as numbness in her 
fingers and plantar fascitis. She was treated 
with pregabalin at 100 mg. She reported of 
cognitive decline following chemotherapy. 
She had a course of radiation was referred 
for a neuropsychological evaluation.
Patient 2 denied ever having a head in-
jury, loss of consciousness, seizure or any 
neurological disorder. She denied any his-
tory of toxic chemical exposure. She also 
denied that her mother experienced any 
perinatal problems or difficulties with labor 
and delivery of Patient 2. Patient 2 denied 
tobacco use and drinks alcohol socially (1-2 
drinks). She denied using illicit drugs. Her 
neuropsychological evaluation took place 3 
months after her chemotherapy ended.
Chief Complaint: Patient 2 complained 
that her thoughts were “fuzzy” and that 
she forgets what she is going to say. She 
also reported memory difficulties including 
forgetting things she has been asked her to 
do, and forgetting well-know things (i.e., 
the name of a computer system that she 
previously used every day at work). 
Psychiatric History: Patient 2 saw a 
social worker sporadically for cognitive 
behavioral therapy and psychoeducation 
during her cancer treatment. She had no 
prior psychiatric history. During her cancer 
treatment, she received mindfulness medi-
tation to help her with stress reduction. 
Patient 2 had insomnia post-treatment and 
tried meditation to help her relax. 
Psychosocial/Occupational/Academic 
Functioning: Patient 2 was single and worked 
as an account supervisor at an advertising 
agency. She was on short-term disability for 
7 months prior to the neuropsychological 
evaluation. Patient 2 had concerns about 
being able to keep up with the details of 
managing accounts when she eventually 
returned to work. She did well in school 
and reported receiving mostly A’s and B’s 
in high school. She denied ever being 
diagnosed with a learning disability or 
attention deficit disorder. She was in gifted 
classes when she was younger and in high 
school, took accelerated classes in English 
and Math. Patient 2 had a Bachelor’s 
degree in business and a Master’s degree 
in marketing and communications from a 
competitive university. Patient 2 reported 
having a good support system with her 
family and boyfriend as well as friends 
from the schools she attended. Prior to her 
diagnosis, she enjoyed dancing and was 
regularly involved in this activity. 
Behavioral Observations: Patient 2 was 
alert and oriented in all spheres. Patient 2’s 
gait appeared stiff. No extraneous move-
ments were observed. She had reported 
limited mobility in her nondominant, left 
hand. Her speech was fluent and of normal 
rate and volume. Patient 2 was very per-
sonable, friendly, and made good eye-con-
tact. Her attitude toward testing was posi-
tive, and she exerted good effort working 
diligently on all tasks presented. Mood was 
euthymic. Patient 2 demonstrated a logical 
and organized thought process. There was 
no evidence of hallucinations, delusions, 
or compulsions. Patient 2 appeared to have 
insight into her cognitive problems. Judg-
ment was intact. The assessment appeared 
to be an accurate representation of her cur-
rent cognitive functioning. 
Neuropsychological Assessment (see 
Table 1 for the various neuropsychological 
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Table 4. Patient 2: First Neuropsychological Evaluation
(3 months post-chemotherapy)
Test Score Percentile Interpretation Norms/Reference
Motivation
TOMM Tombaugh, 1996(47)
Trial 1 48/50 Valid
Trial 2 49/50 Valid
CPT-II Valid Conners, 2004(42)
Reliable Digit Span Raw=8 >25 Above cut-off Pearson, 2009(38)
CVLT-II Forced Choice Raw=16/16 Valid Delis, et al. 2000(41)
PAI T-Score Morey, 2009(34)
Inconsistency 37
Infrequency 44
Negative Impression Management 44
Positive Impression Management 50 Slightly Elevated
Premorbid IQ Estimate
WRAT-4  Standard Score Percentile Wilkinson, 2006(50)
Word Reading 108 70 Average
Attention
WAIS-IV  Standard Score Percentile Wechsler, 2008(48)
Working Memory Index 92 30 Average
Working Memory Subtests Scaled Score Percentile
Arithmetic  8 25 Low Average
Digit Span  9 37 Average
 Digit Span Forward  9 37 Average
 Digit Span Backward  8 25 Low Average
 Digit Span Sequencing 10 50 Average
Continuous Performance Test-II T-Score* Percentile Conners, 2004(42)
Omissions 275 99 Markedly 
Atypical
Commissions  49 49 Within Normal
Hit RT  67 96 Atypically Slow
Hit RT SE  86 99 Markedly 
Atypical
Variability  82 99 Markedly 
Atypical
Detectability  58 79 Mildly Atypical
Response Style  42 23 Mildly Atypical
Perseverations  85 99 Markedly 
Atypical
Hit RT Block Change  73 99 Markedly 
Atypical
Hit SE Block Change  87 99 Markedly 
Atypical
Hit RT ISI Change  62 90 Mildly Atypical
Hit SE ISI Change  80 99 Markedly 
Atypical
*Scores are reversed scored
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Information Processing Speed
WAIS-IV Standard Score Percentile Wechsler, 2008(48)
Processing Speed Index 108 70 Average
Processing Speed Subtests Scaled Score Percentile 
Coding 15 95 Superior
Symbol Search  8 25 Low Average
Trail Making T-Score Percentile Heaton et al. 2004(40)
Trails A 53 62 Average
Language Functioning
Boston Naming Test Raw Score Percentile Heaton et al. 2004(40)
Spontaneously Correct 57/60 66 Average
Verbal Fluency Scaled Score Percentile
Letter Fluency T=48 42 Average Heaton et al. 2004(40)
Category Fluency 14 91 Superior Delis et al. 2001(44)
Visual Spatial
Rey Complex Figure Test Raw Score Percentile Meyers & Meyers, 1995(35) 
Copy 36 >16 Within Normal
Executive Functioning
Trail Making T-Score Percentile Heaton et al. 2004(40)
Trails B 56 73 Average
Color Word Interference Scaled Score Percentile Delis et al. 2001(44)
Color Naming 13 84 High Average
Word Reading 15 95 Superior
Inhibition 11 63 Average
Inhibition Total Errors  7 16 Low Average
Inhibition/Switching 10 50 Average
Inhibition/Switching Total Errors 11 63 Average
Wisconsin Card Sorting Test T-Score Percentile Heaton, 2005(37)
Categories Raw=6 >16 Within Normal
Trials to First Category Raw=18 6-10% Mildly Impaired
PSV Responses T=40 16 Low Average
PSV Errors T=41 18 Low Average
% Conceptual Level Responses T=42 24 Low Average
Failure to Maintain Set Raw=0 >16 Within Normal
Learning to Learn Raw=7.78 >16 Within Normal
Memory
Wechsler Memory Scale-IV Scaled Score Percentile Wechsler, 2009(49)
Logical Memory I 7 16 Low Average
Logical Memory II 6 9 Mildly Impaired
Recognition Raw=21/30 10-16 Low Average
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CVLT-II z-Score Percentile Delis, et al. 2000(41)
Learning Slope 0 50 Average
Trials 1-5 Total T=57 76 High Average
SDFR 0.5 69 Average
SDCR 0.5 69 Average
LDFR 0.5 69 Average
LDCR 0 50 Average
Recognition 0 50 Average
False Positives -0.5 31 Average
Rey Complex Figure Test T-Score Percentile Meyers & Meyers, 1995(35)
Immediate Recall 59 82 High Average
Delayed Recall 56 73 Average
Recognition 20/24 >16 Within Normal
Behavioral and Emotional Functioning
BDI-Fast Screen Raw Score
Total Depression Score 4/21 Mild Symptoms    Beck, 2000(39)
PAI T Score    Morey, 2009(34)
Inconsistency 37
Infrequency 44
Negative Impression Management 44
Positive Impression Management 50 Slightly 
Elevated
Somatic Complaints 57
Anxiety
Anxiety-Related Disorders
Depression
Mania
Paranoia
Schizophrenia
Borderline Features
Antisocial Features
Alcohol Problems
Drug Problems
Aggression
Suicidal Ideation
Stress
Nonsupport
Treatment Rejection
Dominance
Warmth
52
51
54
56
41
49
54
48
45
42
54
43
55
39
46
60
65 Elevated
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tests used in the case studies presented). 
Table 4 presents the individual neuropsy-
chological tests used with Patient 2. Tests 
that were 1.5 standard deviations below 
the premorbid IQ estimate were consid-
ered lower than expected. 
Tests of motivation indicated that 
Patient 2 put forth her best effort on 
the neuropsychological tasks. On a 
personality inventory, she had a slight 
tendency to present herself favorably, 
free of common shortcomings. Patient 2’s 
neuropsychological profile is indicative 
of deficits in attention and executive 
functioning. On a continuous performance 
test, she produced a strikingly atypical 
profile marked by extremely poor 
attentional capacity and vigilance deficits. 
Though her commission error rate was 
within normal limits, she made substantially 
more omission errors than same aged 
peers, and she produced significantly more 
omission errors as the test advanced. Her 
performance was inconsistent, erratic, and 
her reaction time was slow, particularly 
as the test progressed and as the tempo 
of the stimuli presentation slowed. In 
addition, Patient 2 had difficulty detecting 
the stimuli from the non-stimuli. On an 
executive functioning task measuring 
reciprocal inhibition, her errors were low 
average, a performance which was lower 
than expected for her (given her premorbid 
IQ estimate). On a measure of concept 
formation and problem solving, she 
generally performed within normal limits 
but it took her longer than same-aged peers 
to consistently implement a strategy (mildly 
impaired). Overall her memory functioning 
was adequate with the exception of 
narrative recall. While story memory is 
usually better than word list retrieval, her 
fluctuating attention may have impacted 
her recall of narratives. Her memory 
for narratives was lower then expected 
(given her premorbid IQ estimate) at the 
immediate recall and mildly impaired after 
a half-hour delay. Patient 2 also appeared 
to be exhibiting some mild depression and 
posttraumatic anxiety related to her cancer 
and fears of recurrence (based on her 
individual responses to a few items about 
post-traumatic stress). However, her mild 
depression and anxiety was not wholly 
responsible for her cognitive deficits. 
Without a premorbid neuropsychological 
assessment (conducted prior to her cancer 
and its treatment), it is impossible to 
determine the exact causation of Patient 
2‘s cognitive difficulties. However, her 
negative premorbid history for cognitive 
problems, her neuropsychological 
profile, and her subjective complaints 
are consistent with chemotherapy-related 
cognitive side-effects. Patient 2 was not 
interested in medication for her attentional 
problems. Cognitive rehabilitation was 
recommended to ameliorate her attention 
and executive functioning deficits with the 
eventual goal of being able to return to 
her former occupation and perform at her 
previous high-level of functioning.
Occupational Therapy
Patient 2 presented to Occupational 
Therapy for evaluation and treatment 
of cognitive deficits after her neuro psy-
chological evaluation. Of note, she had 
previously been seen by Occupational 
Therapy for left hand fine motor 
deficits secondary to her chemotherapy 
extravasation. For the purpose of this paper, 
we will describe the Occupational Therapy 
interventions targeted at addressing her 
cognitive deficits. Patient 2 reported no 
difficulty managing her basic or instrumental 
activities of daily living due to cognitive 
deficits. No safety concerns were identified 
during initial evaluation or throughout the 
course of treatment. Patient 2 completed 
the Montreal Cognitive Assessment 
(MOCA)(31) with a score of 27/30. Areas of 
deficit were identified to include attention/
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calculation and memory. Patient 2 was 
able to complete 2/5 correct calculations 
during Serial 7’s, and able to successfully 
recall 3/5 novel items. The additional 2 
items she was able to recall with category 
cues. She reported that 2 weeks prior to 
initiating Occupational Therapy, she felt as 
though she was “pushing through a fog” to 
think. At the time of evaluation, she stated 
she “just feel[s] blank.” She reported word-
finding difficulties during conversation and 
was anxious about returning to work in the 
near future.
At the time of the evaluation, it was 
determined that Patient 2 would attend 
one Occupational Therapy treatment 
session each week for 8 weeks. Again, 
the frequency was determined in order 
to allow time for strategy implementation 
between sessions. The duration of 8 weeks 
of therapy intervention was determined by 
the level of Patient 2’s deficits as well as 
the additional goal of transitioning back 
to work. At the completion of the 8 weeks 
of Occupational Therapy intervention, re-
evaluation was performed, and Patient 
2 was scheduled for an additional 6 
treatment sessions. It is important to note 
that the additional treatment sessions 
were primarily to address limited thumb 
mobility and strength due to a previous 
chemotherapy extravasation, however 
any ongoing cognitive issues were also 
addressed. 
Patient 2 completed a total of 14 
treatment sessions, mostly addressing 
cognitive deficits. Interventions included 
in treatment sessions addressed 
memory (with content presented both 
visually and aurally), organizational 
strategies, functional organization and 
communication of information, relaxation/
visualization techniques and remediation 
of divided attention and set-shifting. A 
wide range of activities were implemented 
to address these deficits. Patient 2 typed a 
self- and clinician- generated compensatory 
strategies sheet for improving functional 
memory during work meetings. This sheet 
including such tasks such as taking notes, 
using post-its, marking or highlighting items 
to which she should return. Contextual 
strategies for working memory and delayed 
recall included creating a sentence or short 
story linking items to be remembered. 
Office computer software programs such 
as Power-Point and Excel were used to 
synthesize and communicate provided 
information, in order to simulate the work 
task of preparing presentations. Computer-
based games were used to improve ability 
with divided attention and set-shifting. 
Patient 2 reported difficulty with getting 
adequate rest at night due to rumination 
and difficulty relaxing. She felt fatigue 
was impacting her performance at work, 
specifically impacting her attention and 
memory. Patient 2 was taught relaxation 
techniques to improve nighttime rest, 
including counting backwards, progressive 
muscle relaxation, and visualization. Of 
note, during the treatment session where 
the patient was instructed with these 
techniques, she was yawning after practicing 
these techniques, and reported she will try 
to implement them consistently at home. 
After 8 Occupational Therapy sessions, 
Patient 2 was re-evaluated. The Mini-Mental 
State Exam (MMSE)(36) was administered at 
the re-evaluation, with the patient scoring 
30/30. While she completed 4/5 Serial 7 
calculations correctly, she was able to spell 
the word, “world,” backward, receiving 
full credit for the attention/calculation 
component of this assessment. By this 
time, she had returned to work part-time. 
She stated she had ongoing difficulty with 
organizing the flow of work presentations 
and remembering connections between 
topics, however, she found that rehearsing 
her presentations was helpful. Notably, this 
was a strategy that she had not needed 
to implement prior to her chemotherapy 
treatment. 
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Additional treatment sessions were 
focused on developing and practicing 
compensatory strategies to assist with 
organization and flow of work-related 
presentations. Activity-based intervention 
to address these difficulties included asking 
Patient 2 to read a self-selected New York 
Times article and start creating a Power-Point 
presentation summarizing the salient features 
of the article. She required increased time 
with this task, stating the task demonstrated 
exactly what she has difficulty doing at 
work. Strategies such as highlighting items 
to be included in the presentation as well 
as creating an initial outline were discussed, 
with Patient 2 reporting that she would try 
implementing such strategies at work. 
Upon discharge from Occupational 
Therapy, Patient 2 continued to work part-
time. The Montreal Cognitive Assessment 
(MOCA)(31) was administered at this time, 
with Patient 2 scoring 28/30. Improvements 
were noted with attention/calculation 
component of Serial 7’s in comparison to 
initial administration on evaluation. Upon 
discharge, the patient miscalculated the 
first subtraction, however all subsequent 
subtractions were correct based on that 
miscalculation. Thus, Patient 2 received 
full credit for this component. The area 
in which she continued to demonstrate 
deficit was in delayed recall, again 
recalling 3/5 items and requiring cuing for 
the additional 2 items. However, this type 
of task is one that is easily compensated for 
during daily activity through either note-
taking or utilizing a contextual strategy. 
Upon completion of Occupational 
Therapy treatment, Patient 2 demonstrated 
understanding of these strategies.
Reflection
Patient 2 was engaged and consistent 
with the therapy process. She was open to 
learning and implementing compensatory 
strategies to improve success at work, 
while working towards remediating deficits 
in her attention and memory. Part of this 
engagement in the therapy process may 
be due to meeting her Occupational 
Therapist(33) prior to initiating Occupational 
Therapy to address her cognitive deficits. 
GM initially met Patient 2 at the time of 
her chemotherapy extravasation. Patient 
2 was referred for orthotic fabrication to 
immobilize her thumb and wrist after the 
extravasation. It is possible that due to 
rapport developed during those 2-3 visits, 
the patient felt more comfortable with her 
Occupational Therapist(33) and was thus 
more engaged in the therapeutic process.
The most significant barrier to Patient 
2’s success regarding her return to work 
full-time was the intensity of her work 
environment. Patient 2 worked in an 
extremely fast-paced, high-demand setting 
with multiple teams and varied leadership. 
Part of her role within this structure was 
to facilitate communication between these 
different parties, leading to very detailed 
and high-demand work. Patient 2 was often 
required to meet immediate deadlines and 
work 14-16 hour days. Despite working 
part-time upon completing Occupational 
Therapy, Patient 2 was still putting in 
extra hours at home in order to complete 
her required work. Additional barriers to 
successful outcomes included Patient 2’s 
external stressors (financial, familial -- 
elderly parents who lived 120 miles away) 
as well as her inadequate nightly rest.
Neuropsychological Re-Evaluation: 
Table 5 presents the individual 
neuropsychological tests used in Patient 
2’s re-evaluation. Tasks that Patient 2 had 
difficulty with were repeated (see Table 1 
for all neuropsychological tests). Tests that 
were 1.5 standard deviations below the 
premorbid IQ estimate were considered 
lower than expected.
Patient 2 was re-evaluated 2 weeks after 
her course of Occupational Therapy treat-
ment and 9 months post-chemotherapy. 
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Table 5. Patient 2: Comparison of Neuropsychological Scores on Selective Tests 
Found to be Impaired or Lower than Expected
Premorbid IQ Estimate
WRAT-4
Word Reading
Standard Score
108
Percentile
70
Interpretation
Average
Baseline
(3 Months Post-Chemotherapy)
Re-Evaluation after OT 
(9 Months Post-Chemotherapy)
Test Score % Interpretation Score % Interpretation
Attention
WAIS-IV  Standard %  Standard %
Working Memory Index 92 30 Average 92 30 Average
Working Memory Subtests Scaled % Scaled %
Arithmetic 8 25 Low Average 8 (10 )^ 25 Low Average
^Test the Limits
Digit Span 9 37 Average 9 37 Average
  Digit Span Forward 9 37 Average 10 50 Average
  Digit Span Backward 8 25 Low Average 8 25 Low Average
  Digit Span Sequencing 10 50 Average 8 25 Low Average
Continuous Performance Test-II T Score* % T-Score* %
Omissions 27.5 99 Markedly Atypical 62 90 Mildly Atypical
Commissions 49 49 Within Normal 56 74 Within Normal
Hit RT 67 96 Atypically Slow 47 42 Within Normal
Hit RT SE 86 99 Markedly Atypical 54 66 Within Normal
Variability 82 99 Markedly Atypical 54 68 Within Normal
Detectability 58 79 Mildly Atypical 62 90 Mildly Atypical
Response Style 42 23 Mildly Atypical 42 23 Mildly Atypical
Perseverations 85 99 Markedly Atypical 46 38 Within Normal
Hit RT Block Change 73 99 Markedly Atypical 49 47 Within Normal
Hit SE Block Change 87 99 Markedly Atypical 62 90 Mildly Atypical
Hit RT ISI Change 62 90 Mildly Atypical 57 77 Within Normal
Hit SE ISI Change 80 99 Markedly Atypical 66
95
Markedly 
Atypical
*Scores are reversed scored
Executive Functioning
Color Word Interference Scaled % Scaled %
Color Naming 13 84 High Average 11 63 Average
Word Reading 15 95 Superior 11 63 Average
Inhibition 11 63 Average 11 63 Average
Inhibition Total Errors  7 16 Low Average  9 37 Average
Inhibition/Switching 10 50 Average 10 50 Average
Inhibition Switching Errors 11 63 Average 12 75 High Average
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Wisconsin Card Sorting Test T Score % T-Score %
Categories Raw=6 >16 Within Normal Raw=5 11-16 Low Average
Trials to First Category Raw=18 6-10 Borderline Raw=11 >16 Low Average
PSV Responses T=40 16 Low Average 30 2 Impaired
PSV Errors T=41 18 Low Average 32 4 Borderline
% Conceptual Level Responses T=42 24 Low Average 42 21 Low Average
Failure to Maintain Set Raw=0 >16 Within Normal Raw=5 ≤1 Impaired
Learning to Learn Raw=
7.78
>16 Within Normal Raw=
-4.85
6-10 Borderline
Memory
Wechsler Memory Scale-IV Scaled % Scaled %
Logical Memory I  7 16 Low Average 11 63 Average
Logical Memory II  6  9 Mildly Impaired 11 63 Average
Recognition Raw= 
21/30
10-
16
Low Average Raw= 
21/30 
10-16 Low Average
she improve her daily functioning during 
that time? This quandary is highlighted in 
these case studies of young women who 
are working and having difficulty in fast-
paced, multi-tasking work environments. 
The primary role of Occupational Therapy 
in this population is to facilitate improved 
daily functioning. 
It is important to note that working 
in conjunction with neuropsychology, a 
better delineation of a patient’s cognitive 
difficulties can be made than solely 
relying on screening measures such as 
the MOCA(31) or the MMSE(36). For Patient 
1, her pre-therapy MOCA score of 30/30 
was inconsistent with her perception 
of self-functioning that was below her 
premorbid level of cognitive functioning. 
This perception was validated by her 
deficits on neuropsychological testing. 
Tailoring remediation and compensatory 
strategies to the patient in order to address 
both demonstrated and reported deficits 
is crucial. However, neuropsychological 
evaluation occurs in an environment free 
from distractions which diminishes its 
ecological validity. Occupational Therapy 
intervention requires understanding the 
impact of the patient’s deficits in their 
daily life, whether the challenges are at 
Her neuropsychological profile re-
vealed some improvements but in some 
areas she continued to have difficulty. She 
improved in verbal memory for narratives. 
Her total errors on reciprocal inhibition 
also improved. However, Patient 2’s per-
formance indicated continued attentional 
difficulties and executive dysfunction, 
consistent with chemotherapy-related cog-
nitive side effects. While her performance 
on a continuous performance test was 
improved, Patient 2 continued to demon-
strated problems maintaining attention and 
a significant decrement in her ability to 
maintain a problem-solving strategy. Her 
difficulty on the Wisconsin Card Sorting 
Test(37) was particularly notable as this test 
has such a pronounced practice effect.
CONCLUSION
As demonstrated by these cases, a 
tailored Occupational Therapy interven-
tion tends to be better at helping patients 
compensate for difficulties rather than 
completely restoring premorbid cognitive 
functioning. While chemotherapy-related 
cognitive deficits typically resolve within 
12-18 months(5), it still begs the ques-
tion: What is a person to do and how can 
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one’s job or managing one’s household. 
Working to document in descriptive terms 
the quality of the patient’s performance 
on tasks helps contextualize her deficits 
in environments outside of the therapy 
and also assists in measuring improvement 
in the quality of the patient’s functional 
performance over the course of treatment. 
Improving a half a standard deviation on 
a neuropsychological test is meaningless 
without such descriptive information.
Future directions 
Future directions for research include 
using advances in technology to delineate 
the neural mechanisms underlying cogni-
tive rehabilitation. Using structural and 
functional neuroimaging may help de-
termine whether a tailored Occupational 
Therapy intervention changes brain struc-
ture and function and/or affects compensa-
tory mechanisms.
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